AB

Ascendant BioCapital

North America, Delaware, United States, Wilmington

Description

Ascendant BioCapital is a venture capital firm.

Investor Profile

Ascendant BioCapital has made 2 investments, with 0 in the past 12 months and 50% as lead.

Stage Focus

  • Series B (50%)
  • Series A (50%)

Country Focus

  • United States (50%)
  • The Netherlands (50%)

Industry Focus

  • Biotechnology
  • Life Science
  • Pharmaceutical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Ascendant BioCapital frequently co-invest with?

EcoR1 Capital
North America, California, United States, San Francisco
Co-Investments: 1
CA
North America, Massachusetts, United States, Boston
Co-Investments: 1
Alexandria Venture Investments
North America, California, United States, Pasadena
Co-Investments: 1
Samsara BioCapital
North America, California, United States, Palo Alto
Co-Investments: 1
Casdin Capital
North America, New York, United States, New York
Co-Investments: 1
Avidity Partners
North America, Texas, United States, Dallas
Co-Investments: 1
Biotechnology Value Fund
North America, California, United States, San Francisco
Co-Investments: 1
ArrowMark Partners
North America, Colorado, United States, Denver
Co-Investments: 1
BlackRock
North America, New York, United States, New York
Co-Investments: 1
Redmile Group
North America, California, United States, San Francisco
Co-Investments: 1

Which angels does Ascendant BioCapital often collaborate with?

PT
North America, California, United States, San Francisco
Shared Deals: 1

What are some of recent deals done by Ascendant BioCapital?

New Amsterdam Pharma

Naarden, Noord-Holland, The Netherlands

New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.

BiotechnologyLife SciencePharmaceutical
Series AJan 14, 2021
Amount Raised: $194,412,819
Neurogene

New York, New York, United States

Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.

Biotechnology
Series BDec 16, 2020
Amount Raised: $115,000,000